{"id":"treatment-with-caz-avi","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Phlebitis at infusion site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Avibactam is a beta-lactamase inhibitor that protects ceftazidime from degradation by serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases, and some carbapenemases. This combination restores the activity of ceftazidime against resistant gram-negative bacteria.","oneSentence":"CAZ-AVI is a combination of ceftazidime and avibactam that works by inhibiting bacterial beta-lactamases while ceftazidime attacks the bacterial cell wall.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:17.822Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria"},{"name":"Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)"},{"name":"Complicated intra-abdominal infections (cIAI)"},{"name":"Gram-negative infections in patients with limited treatment options"}]},"trialDetails":[{"nctId":"NCT07478484","phase":"PHASE4","title":"Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB","status":"RECRUITING","sponsor":"Jing Zhou","startDate":"2026-03-31","conditions":"Ceftazidime-avibactam, Aztreonam, Gram-negative Bacterial Infection","enrollment":144},{"nctId":"NCT06717594","phase":"","title":"PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2023-12-01","conditions":"Gram Negative Infections, Antimicrobial Resistance (AMR)","enrollment":60},{"nctId":"NCT07063095","phase":"PHASE3","title":"A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections","status":"RECRUITING","sponsor":"Angela HUTTNER","startDate":"2025-08-25","conditions":"Gram Negative Infections, Sepsis and Septic Shock","enrollment":100},{"nctId":"NCT05413343","phase":"","title":"Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-06-01","conditions":"Severe Sepsis","enrollment":30},{"nctId":"NCT06939829","phase":"PHASE4","title":"A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections","status":"NOT_YET_RECRUITING","sponsor":"Southeast University, China","startDate":"2025-05-01","conditions":"Patients With Critically Ill Infections","enrollment":1200},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-26","conditions":"Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia","enrollment":60},{"nctId":"NCT06651047","phase":"","title":"PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections","status":"RECRUITING","sponsor":"University of Bologna","startDate":"2024-07-09","conditions":"Gram Negative Infection, Antimicrobial Resistance (AMR)","enrollment":120},{"nctId":"NCT06528028","phase":"PHASE4","title":"Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-07-01","conditions":"Anti-Infective Agent","enrollment":140},{"nctId":"NCT05258851","phase":"PHASE3","title":"Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections","status":"TERMINATED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2022-06-01","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":29},{"nctId":"NCT05850871","phase":"NA","title":"Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-01-06","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":427},{"nctId":"NCT03790176","phase":"PHASE1","title":"ZAVI APD ELF Protocol v2.2","status":"UNKNOWN","sponsor":"Markus Zeitlinger","startDate":"2018-10-01","conditions":"Peritonitis, Pneumonia","enrollment":20},{"nctId":"NCT02475733","phase":"PHASE2","title":"Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-08-01","conditions":"Complicated Intra-abdominal Infections","enrollment":83},{"nctId":"NCT02497781","phase":"PHASE2","title":"Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-09-24","conditions":"Complicated Urinary Tract Infections","enrollment":97},{"nctId":"NCT01644643","phase":"PHASE3","title":"Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-01","conditions":"Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection","enrollment":345},{"nctId":"NCT01599806","phase":"PHASE3","title":"Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-10","conditions":"Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis","enrollment":641},{"nctId":"NCT01499290","phase":"PHASE3","title":"Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-03","conditions":"Complicated Intra-Abdominal Infection","enrollment":493},{"nctId":"NCT01808092","phase":"PHASE3","title":"A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP)","enrollment":969},{"nctId":"NCT01595438","phase":"PHASE3","title":"Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-10","conditions":"Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis","enrollment":598},{"nctId":"NCT01893346","phase":"PHASE1","title":"Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Systemic Infections","enrollment":35},{"nctId":"NCT02732327","phase":"PHASE2","title":"Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2016-05-17","conditions":"Neoplasms, Febrile Neutropenia","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":271,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"treatment with CAZ-AVI","genericName":"treatment with CAZ-AVI","companyName":"Southeast University, China","companyId":"southeast-university-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CAZ-AVI is a combination of ceftazidime and avibactam that works by inhibiting bacterial beta-lactamases while ceftazidime attacks the bacterial cell wall. Used for Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria, Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), Complicated intra-abdominal infections (cIAI).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}